JBT Marel (JBTM) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Aug, 2026Executive summary
Orders and backlog increased 10% year-over-year, with orders exceeding $1 billion and a book-to-bill ratio of 1.05x, reflecting strong demand across key end markets.
Revenue and adjusted EBITDA margin were near the low end of guidance due to delayed backlog-to-revenue conversion from logistics and manufacturing inefficiencies in the Prepared Food and Beverage Solutions segment.
Net income for Q2 2026 was $28 million, up from $3 million in Q2 2025, despite a $33 million non-cash impairment charge related to a 2021 acquisition.
Integration of complementary technologies and footprint optimization are advancing, with synergy realization and restructuring underway.
Year-to-date free cash flow was $179 million, supporting rapid deleveraging and strong liquidity.
Financial highlights
Q2 2026 revenue reached $981 million, up 5% year-over-year (3% organic, 2% FX), with gross profit margin increasing to 36.6%.
Adjusted EBITDA was $168 million (17.1% margin), up from $156 million (16.7%) year-over-year.
Net income margin was 2.9%, and adjusted EPS was $1.95, up from $1.49 year-over-year.
Free cash flow for Q2 2026 was $79 million; for the first half of 2026, $179 million.
Leverage ratio at quarter-end was 2.47x, within the target range of 2x-2.5x.
Outlook and guidance
Full-year 2026 revenue guidance is $3.99–$4.07 billion, up 5–7% year-over-year, including a 1.5% FX benefit.
Adjusted EBITDA margin guidance is 17.0–17.5%; adjusted EPS guidance is $7.85–$8.35; GAAP EPS $4.20–$4.70, reflecting the Q2 impairment charge.
Margin improvement expected in Prepared Food and Beverage Solutions in H2 2026, supported by backlog, pricing, and operational initiatives.
Protein Solutions margins expected to remain flat in H2, with a higher equipment mix.
Capex expected at $105–$120 million; tax rate ~24%.
Latest events from JBT Marel
- Merger creates a global food tech leader with strong synergies, closing by year end 2024.JBTM
Business Combination8 Jul 2026 - Q1 2025 revenue hit $854M, but one-time charges drove a $173M net loss; outlook cautious.JBTM
Q1 20258 Jul 2026 - $3.9B TTM revenue, 16.2% EBITDA margin, and strong recurring revenue drive growth and resilience.JBTM
Investor presentation31 May 2026 - All director nominees and proposals were approved, with no questions from stockholders.JBTM
AGM 202614 May 2026 - Q1 2026 saw 10% revenue growth, $45M net income, and strong Protein Solutions margin gains.JBTM
Q1 202612 May 2026 - 2025 saw record revenue and synergy gains, with 2026 set for further growth and margin expansion.JBTM
Q4 202511 Apr 2026 - Annual meeting to elect directors, approve pay, and ratify auditor, with board support.JBTM
Proxy filing1 Apr 2026 - Proxy details director elections, pay-for-performance, and strong ESG focus after a transformative merger.JBTM
Proxy filing1 Apr 2026 - Targeting 5–7% organic growth and >20% EBITDA margin by 2028 through digital integration.JBTM
Investor Day 202626 Mar 2026